Labeler
Novo Nordisk NDC Codes
Novo Nordisk lists 69 finished drug products in the FDA NDC Directory under NDC labeler code 0169.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- NovoSeven RT, Esperoct, Novoeight, Novolog, Rebinyn, Fiasp, Norditropin, NovoLog Mix 70/30, Alhemo, Rivfloza, Sogroya, Tresiba, Zegalogue, Novolin R, Novolin N
- Active ingredients
- Insulin aspart, Insulin human, Insulin degludec, Somatropin, Concizumab, Nedosiran sodium, Somapacitan, Dasiglucagon, Liraglutide, Macimorelin, Estradiol, Water
- NDC labeler codes
- 0169
- Strengths
- Insulin aspart 100 [iU]/mL; Insulin human 100 [iU]/mL; Concizumab 100 mg/mL; Dasiglucagon .6 mg/.6mL; Insulin degludec 100 U/mL; Concizumab 40 mg/mL; Nedosiran sodium 160 mg/mL; Nedosiran sodium 128 mg/.8mL; Nedosiran sodium 80 mg/.5mL; Somapacitan 6.7 mg/mL; Somapacitan 3.3 mg/mL; Somapacitan 10 mg/mL; Macimorelin 60 mg/mg; Insulin degludec 100 [iU]/mL; Liraglutide 3.6 mg/mL; Insulin degludec 200 U/mL; Liraglutide 6 mg/mL; Estradiol 10 ug/1; Somatropin 30 mg/3mL; Somatropin 10 mg/1.5mL
- Dosage forms
- Injection, Solution, Kit, Injection, Suspension, Granule, For solution, Injection, Insert
- Routes
- Subcutaneous, Intravenous, Oral, Vaginal
- Drug classes (FDA established)
- Insulin Analog, Insulin, Recombinant Human Growth Hormone, Tissue Factor Pathway Inhibitor Antagonist, Antihypoglycemic Agent, GLP-1 Receptor Agonist, Growth Hormone Secretagogue Receptor Agonist, Estrogen
- HCPCS / J-code
- None in Med-Code's directory for these products
- Package NDCs
- 105
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Alhemoconcizumab | Concizumab 100 mg/mL | Injection, SolutionSubcutaneous | 0169-2080 | 00169-2080-15 | — |
| Alhemoconcizumab | Concizumab 100 mg/mL | Injection, SolutionSubcutaneous | 0169-2081 | 00169-2081-03 | — |
| Alhemoconcizumab | Concizumab 40 mg/mL | Injection, SolutionSubcutaneous | 0169-2084 | 00169-2084-15 | — |
| Rivflozanedosiran | Nedosiran sodium 160 mg/mL | Injection, SolutionSubcutaneous | 0169-5306 | 00169-5306-10 | — |
| Rivflozanedosiran | Nedosiran sodium 128 mg/.8mL | Injection, SolutionSubcutaneous | 0169-5307 | 00169-5307-08 | — |
| Rivflozanedosiran | Nedosiran sodium 80 mg/.5mL | Injection, SolutionSubcutaneous | 0169-5308 | 00169-5308-01 | — |
| Zegaloguedasiglucagon | Dasiglucagon .6 mg/.6mL | Injection, SolutionSubcutaneous | 0169-1912 | 00169-1912-0100169-1912-02 | — |
| Zegaloguedasiglucagon | Dasiglucagon .6 mg/.6mL | Injection, SolutionSubcutaneous | 0169-1913 | 00169-1913-0100169-1913-02 | — |
| Sogroyasomapacitan-beco | Somapacitan 6.7 mg/mL | Injection, SolutionSubcutaneous | 0169-2030 | 00169-2030-1100169-2030-90 | — |
| Sogroyasomapacitan-beco | Somapacitan 3.3 mg/mL | Injection, SolutionSubcutaneous | 0169-2035 | 00169-2035-1100169-2035-90 | — |
| Sogroyasomapacitan-beco | Somapacitan 10 mg/mL | Injection, SolutionSubcutaneous | 0169-2037 | 00169-2037-1100169-2037-90 | — |
| Rebinyncoagulation factor ix recombinant, glycopegylated | — | Kit | 0169-7903 | 00169-7903-01 | — |
| Macrilenmacimorelin acetate | Macimorelin 60 mg/mg | Granule, For solutionOral | 0169-1401 | 00169-1401-01 | — |
| Novolin Rhuman insulin | Insulin human 100 [iU]/mL | Injection, SolutionSubcutaneous | 0169-3003 | 00169-3003-1500169-3003-25 | — |
| Novolin Nhuman insulin | Insulin human 100 [iU]/mL | Injection, SuspensionSubcutaneous | 0169-3004 | 00169-3004-1500169-3004-25 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8500 | 00169-8500-0100169-8500-93 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8055 | 00169-8055-01 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8100 | 00169-8100-0100169-8100-93 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8150 | 00169-8150-01 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8200 | 00169-8200-01 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8300 | 00169-8300-0100169-8300-93 | — |
| Esperoctantihemophilic factor (recombinant), glycopegylated-exei | — | Kit | 0169-8400 | 00169-8400-01 | — |
| Tresibainsulin degludec | Insulin degludec 100 U/mL | Injection, SolutionSubcutaneous | 0169-2662 | 00169-2662-1100169-2662-90 | — |
| Novolin 70/30human insulin | Insulin human 100 [iU]/mL | Injection, SuspensionSubcutaneous | 0169-3007 | 00169-3007-1500169-3007-25 | — |
| Rebinyncoagulation factor ix recombinant, glycopegylated | — | Kit | 0169-7901 | 00169-7901-0100169-7901-97 | — |
| Rebinyncoagulation factor ix recombinant, glycopegylated | — | Kit | 0169-7902 | 00169-7902-0100169-7902-97 | — |
| Rebinyncoagulation factor ix recombinant, glycopegylated | — | Kit | 0169-7905 | 00169-7905-0100169-7905-97 | — |
| Fiaspinsulin aspart injection | Insulin aspart 100 [iU]/mL | Injection, SolutionSubcutaneous | 0169-3201 | 00169-3201-1100169-3201-90 | — |
| Fiaspinsulin aspart injection | Insulin aspart 100 [iU]/mL | Injection, SolutionSubcutaneous | 0169-3204 | 00169-3204-1500169-3204-97 | — |
| Fiaspinsulin aspart injection | Insulin aspart 100 [iU]/mL | Injection, SolutionSubcutaneous | 0169-3205 | 00169-3205-1500169-3205-95 | — |
| Fiaspinsulin aspart | Insulin aspart 100 [iU]/mL | Injection, SolutionSubcutaneous | 0169-3206 | 00169-3206-1500169-3206-95 | — |
| Xultophy 100/3.6insulin degludec and liraglutide | Insulin degludec 100 [iU]/mL; Liraglutide 3.6 mg/mL | Injection, SolutionSubcutaneous | 0169-2911 | 00169-2911-15 | — |
| Tresibainsulin degludec | Insulin degludec 200 U/mL | Injection, SolutionSubcutaneous | 0169-2550 | 00169-2550-1300169-2550-97 | — |
| Tresibainsulin degludec | Insulin degludec 100 U/mL | Injection, SolutionSubcutaneous | 0169-2660 | 00169-2660-1500169-2660-97 | — |
| Novoeightantihemophilic factor recombinant | — | Kit | 0169-7810 | 00169-7810-01 | — |
| Novoeightantihemophilic factor recombinant | — | Kit | 0169-7815 | 00169-7815-01 | — |
| Novoeightantihemophilic factor recombinant | — | Kit | 0169-7820 | 00169-7820-01 | — |
| Novoeightantihemophilic factor recombinant | — | Kit | 0169-7825 | 00169-7825-01 | — |
| Novoeightantihemophilic factor recombinant | — | Kit | 0169-7830 | 00169-7830-01 | — |
| Novoeightantihemophilic factor recombinant | — | Kit | 0169-7850 | 00169-7850-01 | — |
| Trettencoagulation factor xiii a-subunit (recombinant) | — | Kit | 0169-7013 | 00169-7013-01 | — |
| Novologinsulin aspart | Insulin aspart 100 [iU]/mL | Injection, SolutionIntravenous, Subcutaneous | 0169-6338 | — | — |
| NovoSeven RTcoagulation factor viia (recombinant) | — | Kit | 0169-7205 | 00169-7205-01 | — |
| NovoSeven RTcoagulation factor viia (recombinant) | — | Kit | 0169-7208 | 00169-7208-01 | — |
| NovoSeven RTcoagulation factor viia (recombinant) | — | Kit | 0169-7201 | 00169-7201-01 | — |
| NovoSeven RTcoagulation factor viia (recombinant) | — | Kit | 0169-7202 | 00169-7202-01 | — |
| NovoSeven RTcoagulation factor viia (recombinant) | — | Kit | 0169-7040 | 00169-7040-01 | — |
| Victozaliraglutide | Liraglutide 6 mg/mL | InjectionSubcutaneous | 0169-4060 | 00169-4060-1200169-4060-1300169-4060-90+1 more | — |
| Vagifemestradiol | Estradiol 10 ug/1 | InsertVaginal | 0169-5176 | 00169-5176-0300169-5176-0400169-5176-99 | — |
| Norditropinsomatropin | Somatropin 30 mg/3mL | Injection, SolutionSubcutaneous | 0169-7703 | 00169-7703-2100169-7703-92 | — |
Novo Nordisk: common questions
- What is Novo Nordisk's NDC labeler code?
- 0169. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Novo Nordisk?
- Med-Code's curated HCPCS directory has no drug-specific code for these products. Drugs dispensed by a pharmacy are billed by NDC. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.